Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled…

Overview of attention for article published in Health and Quality of Life Outcomes, May 2013

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

policy: 1 policy source
twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 60 Dimensions

Readers on

mendeley: 83 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Apremilast

Cited by Canadian Agency for Drugs and Technologies in Health on 05 Oct 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.